These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28958213)

  • 1. Ligand-based virtual screening, molecular docking, QSAR and pharmacophore analysis of quercetin-associated potential novel analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2017 Dec; 37(6):600-610. PubMed ID: 28958213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pamanji R; Yeguvapalli S
    J Recept Signal Transduct Res; 2018 Feb; 38(1):48-60. PubMed ID: 29369008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.
    Bommu UD; Konidala KK; Pabbaraju N; Yeguvapalli S
    J Recept Signal Transduct Res; 2019 Feb; 39(1):18-27. PubMed ID: 31223050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
    Sudha A; Srinivasan P; Rameshthangam P
    J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
    Panicker PS; Melge AR; Biswas L; Keechilat P; Mohan CG
    Chem Biol Drug Des; 2017 Oct; 90(4):629-636. PubMed ID: 28303669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico insights into the identification of potential novel angiogenic inhibitors against human VEGFR-2: a new SAR-based hierarchical clustering approach.
    Konidala KK; Bommu UD; Pabbaraju N
    J Recept Signal Transduct Res; 2018 Aug; 38(4):372-383. PubMed ID: 30396316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
    Chaudhari P; Bari S
    Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
    Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
    J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacophore Based 3D-QSAR, Virtual Screening and Docking Studies on Novel Series of HDAC Inhibitors with Thiophen Linker as Anticancer Agents.
    Patel P; Singh A; Patel VK; Jain DK; Veerasamy R; Rajak H
    Comb Chem High Throughput Screen; 2016; 19(9):735-751. PubMed ID: 27487787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer.
    Ning J; Wu Q; Liu Z; Wang J; Lin X
    J Recept Signal Transduct Res; 2016; 36(1):37-44. PubMed ID: 26096169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study.
    Choubey SK; Jeyaraman J
    J Mol Graph Model; 2016 Nov; 70():54-69. PubMed ID: 27668885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico studies on potential MCF-7 inhibitors: a combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis.
    Badhani B; Kakkar R
    J Biomol Struct Dyn; 2017 Jul; 35(9):1950-1967. PubMed ID: 27401212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
    Agarwal SM; Pal D; Gupta M; Saini R
    Curr Cancer Drug Targets; 2017; 17(7):617-636. PubMed ID: 28359250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
    Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
    Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
    Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
    Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating molecular dynamics-guided lead optimization of EGFR inhibitors.
    Lavecchia MJ; Puig de la Bellacasa R; Borrell JI; Cavasotto CN
    Bioorg Med Chem; 2016 Feb; 24(4):768-78. PubMed ID: 26810832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico analysis of the effect of mutation on epidermal growth factor receptor in non-small-cell lung carcinoma: from mutational analysis to drug designing.
    Zhao FL; Yang GH; Xiang S; Gao DD; Zeng C
    J Biomol Struct Dyn; 2017 Feb; 35(2):427-434. PubMed ID: 26813338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
    Yu H; Li Y; Ge Y; Song Z; Wang C; Huang S; Jin Y; Han X; Zhen Y; Liu K; Zhou Y; Ma X
    Eur J Med Chem; 2016 Mar; 110():195-203. PubMed ID: 26829280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.